Results 161 to 170 of about 24,654 (226)

Drug Overdose Deaths Involving Stimulants - United States, January 2018-June 2024. [PDF]

MMWR Morb Mortal Wkly Rep
Tanz LJ, Miller KD, Dinwiddie AT, Gladden RM, Asher A, Baldwin G, Nesbit B, O'Donnell J.   +7 more
europepmc   +1 more source

A prospective longitudinal analysis of opioid and stimulant use in American Indian and First Nations communities. [PDF]

Addict Behav
Walls M, Hautala D, Sittner KJ, Medley A, Gibbs R.   +4 more
europepmc   +1 more source

Medication vs. Movement in ADHD: Interaction Between Medication and Physical Activity on Neurocognitive Functioning. [PDF]

Brain Sci
Hoy BA, Bi M, Lam M, Abdalmalak A, Fenesi B.   +4 more
europepmc   +1 more source

Psychostimulant effects on motor and cognitive function in adults attention deficit hyperactivity disorder. [PDF]

Int J Neuropsychopharmacol
Cundari M, Kanold L, Bergwall D, Vestberg S, Hansson A, Kirchhoff L, Gustafsson P, Rasmussen A.   +7 more
europepmc   +1 more source

Protracted escitalopram discontinuation syndrome and serotonin toxicity associated with CYP2C19 poor metabolism: A case report. [PDF]

Ment Health Clin
Tran EH, Bishop JR, Brown JT, McIsaac SJ, Schneiderhan ME.   +4 more
europepmc   +1 more source

The rising wave of cathinone use in people attending harm reduction facilities: a French repeated cross-sectional study (2019-2023). [PDF]

Addict Sci Clin Pract
de Ternay J, Plasse A, Rolland B.
europepmc   +1 more source

Commentary on Getty et al.: Complementarity of harm reduction and contingency management. [PDF]

Addiction
Roll JM.
europepmc   +1 more source

Drug overdose deaths in Kentucky, 2019-2024: are we back to Pre-COVID-19 levels? [PDF]

Inj Epidemiol
Smith AP, Lang J, Canedo C, Freeman PR, Hammerslag LR, Harris DR, Kizewski A, Rock P, Seyedtalebi NM, Westgate PM, Talbert J, Walsh SL, Slavova S.   +12 more
europepmc   +1 more source

Drug involvement variations in overdose death spikes: county-level analysis in Massachusetts. [PDF]

BMJ Public Health
Otero-Leon D, Lee H, Dong H, Stringfellow E, Jalali MS.   +4 more
europepmc   +1 more source

Strategic approaches to reducing the substance use-related burden of disease in Canada. [PDF]

Lancet Reg Health Am
Fischer B, Hall W, Le Foll B, Conrod P.
europepmc   +1 more source